Browse by Audience
MEMBER

Update Your Profile
Special Interest Groups (SIG)
Member Spotlights
IASP Connect
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Pain Researcher
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Curricula
Graduate Opportunities
Treatment and Education Resources
Events

PATIENT & CAREGIVER

Resources for Living with Pain
Topic Pages
Free Videos
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner
Make a Donation

I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Baseline Demographics and Severity and Burden of Atopic Dermatitis in Adult Patients Initiating Dupilumab Treatment in a Real-World Registry (PROSE).

< BACK TO ARCHIVE


2022 May 20


Dermatol Ther (Heidelb)


http://www.ncbi.nlm.nih.gov/pubmed/35590038?dopt=Abstract

Baseline Demographics and Severity and Burden of Atopic Dermatitis in Adult Patients Initiating Dupilumab Treatment in a Real-World Registry (PROSE).

Authors

Baseline Demographics and Severity and Burden of Atopic Dermatitis in Adult Patients Initiating Dupilumab Treatment in a Real-World Registry (PROSE).
Bagel J, Nguyen TQ, Lima H, Jain N, Pariser DM, Hsu S, Yosipovitch G, Zhang H, Chao J, Bansal S, Chen Z, Richman D, Korotzer A, Ardeleanu M
Dermatol Ther (Heidelb). 2022 May 20.
PMID: 35590038.

Abstract

Dupilumab was initially approved in 2017 as the first biologic therapy for atopic dermatitis (AD). We characterized adults with AD initiating dupilumab in a real-world setting in the USA/Canada.
Read This Paper